REG - capAI PLC - AGM Trading & Strategic Update

capAIAnnouncement

21/04/2026 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260421:nRSU2095Ba&default-theme=true

RNS Number : 2095B  capAI PLC  21 April 2026

THIS ANNOUNCEMENT ("ANNOUNCEMENT") AND THE INFORMATION CONTAINED HEREIN IS
RESTRICTED AND IS NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR
INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA,
CANADA, JAPAN, SINGAPORE, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER
JURISDICTION IN WHICH SUCH PUBLICATION, RELEASE OR DISTRIBUTION WOULD BE
PROHIBITED BY ANY APPLICABLE LAW.

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF
REGULATION 2014/596/EU, WHICH IS PART OF THE DOMESTIC LAW OF THE UNITED
KINGDOM OF GREAT BRITAIN AND NORTHERN IRELAND ("UK") PURSUANT TO THE MARKET
ABUSE (AMENDMENT) (EU EXIT) REGULATIONS (SI 2019/310) ("UK MAR"). UPON THE
PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION (AS DEFINED IN UK
MAR) IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.

21 April 2026

 capAI plc

 (the "Company" and, together with its subsidiaries, the "Group" or "capAI")

AGM Trading & Strategic Update

capAI plc (LSE: CPAI, OTCQB: CPIQF) is pleased to provide a trading and
strategic update ahead of its Annual General Meeting to be held today, Tuesday
21(st) April 2026.

 

The Company reports continued strong execution across its platform portfolio
and is now entering a key inflection point, with multiple products
transitioning from development into live user availability.

 

Near-Term Product Launches and Platform Momentum

 

·  Game42 (Going Live): Game42, the generative game creation platform, is
scheduled to go live this week. Game42 enables users to transform inputs
ranging from short prompts to full-length books into interactive game
experiences, significantly lowering the barrier to game development and
supporting scalable user-generated content ecosystems.

·   Creator42 / Movie42 (Going Live): Creator42, previously referenced in
earlier communications, will launch this week under the name Movie42. The
platform converts inputs-from a few lines to long-form narratives-into
cinematic, trailer-style video outputs, positioning capAI within the rapidly
expanding AI-driven content creation market.

·  Author42 (Hard Launch): The Company is progressing toward the hard launch
of Author42, its AI-native writing platform. Author42 now includes expanded
capabilities across fiction and memoir writing, alongside advanced editing and
refinement tools, supporting end-to-end content creation and complementing the
broader Game42 and Movie42 ecosystem.

 

Transition to Deployment and Commercial Evaluation

 

With Game42 and Movie42 entering live deployment, capAI is transitioning into
a phase focused on user adoption, iterative improvement and commercial
evaluation. These launches represent a significant step toward validating
product-market fit across multiple verticals.

 

capMedical - Longevity and Healthcare Initiatives

 

Further to the Company's previous RNS announcements, capAI continues to
progress its capMedical initiative, including its focus on AI-enabled
longevity and healthcare applications. A number of potential programmes in
this area remain under active evaluation, with the Company applying its
disciplined venture approach to assess both scientific and commercial
viability before committing further resources.

 

Disciplined Venture Structure (LOA Framework)

 

The Company has to date operated a disciplined venture model, typically
securing opportunities through Licence and Option Agreements (LOAs) that
provide optionality to acquire or license technologies developed in
collaboration with R42.

 

This structure enables capAI to explore and develop multiple initiatives at
relatively low cost, while retaining the ability to capture significant upside
through option-based access to successful projects. By deferring major capital
commitments until technical and commercial viability is clearer, the Company
maintains capital discipline and reduces downside risk. However, shareholders
should note that there can be no guarantee that the Company will ultimately
exercise any option to acquire or license such projects. Decisions to proceed
are made selectively, based on technical progress, market potential and
capital allocation considerations.

 

Outlook

 

The capAI board believes that the transition of multiple platforms into live
availability, combined with a growing pipeline of opportunities under
evaluation, positions capAI for its next phase of growth. The Company remains
focused on disciplined execution, capital efficiency and the selective
advancement of high-potential initiatives.

 

Further updates will be provided in due course.

 

Commenting, Professor Ronjon Nag, Executive Chairman of capAI, said:

 

"We are now seeing the transition of our core platforms from development into
live deployment, which is a critical step in validating both their technical
capability and commercial potential.

 

"At the same time, we continue to apply our disciplined venture approach to
the evaluation of new opportunities, including in AI-enabled longevity and
healthcare, where we believe there is significant long-term value creation
potential. We look forward to providing further updates as these initiatives
progress."

 

For the purposes of UK MAR, the person responsible for arranging release of
this Announcement on behalf of capAI is Professor Ronjon Nag, Executive
Chairman.

 

Enquiries

 

Company:

capAI plc hello@capaiplc.com

 

Broker:

AlbR Capital Limited Tel: +44 (0) 207 469 0930

 

Important Legal Information

The information contained in this Announcement is for background purposes only
and does not purport to be full or complete, nor does this Announcement
constitute or form part of any invitation or inducement to engage in
investment activity. No reliance may be placed by any person for any purpose
on the information contained in this Announcement or its accuracy, fairness or
completeness. The contents of this Announcement are not to be construed as
legal, financial or tax advice.

 

This Announcement does not constitute or form part of any offer or invitation
to sell or issue, or any solicitation of any offer to purchase or subscribe
for, any securities, nor shall it (or any part of it), or the fact of its
distribution, form the basis of, or be relied on in connection with, any
contract therefor.

 

This Announcement may include forward-looking statements, which are based on
current expectations and projections about future events, including about the
Group's operations, strategy, financial performance, development milestones,
and the future prospects of its business divisions, including capMedia Inc,
capMedical Inc, capMedia (UK) Ltd and capMedical (UK) Ltd. These statements
may include, without limitation, any statements preceded by, followed by or
including words such as "target", "believe", "expect", "aim", "intend", "may",
"anticipate", "estimate", "plan", "project", "will", "can have", "likely",
"should", "would", "could" and any other words and terms of similar meaning or
the negative thereof.

 

Forward-looking statements are based on current expectations and are subject
to various risks and uncertainties that could cause actual outcomes to differ
materially. These risks include, but are not limited to: successful execution
of definitive agreements; regulatory approvals; development timelines; market
acceptance; technological shifts; and broader economic conditions. No
representation or warranty is made or will be made that any forward-looking
statement will come to pass, and no assurance can be given that any
forward-looking statement will prove accurate. Except as required by law,
capAI undertakes no obligation to revise or update any forward-looking
statement. The forward-looking statements in this Announcement speak only as
at the date of this Announcement.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDEAELEADSKEAA



            Copyright 2019 Regulatory News Service, all rights reserved